NeuroNata-R

Corestem Shares Protocol for Long-term NeuroNata-R Trial

Corestem is still enrolling participants in its Phase 3 clinical trial of NeuroNata-R (lenzumestrocel), a stem cell therapy that is conditionally approved to treat amyotrophic lateral sclerosis (ALS) in South Korea. The trial, ALSummit (NCT04745299), is evaluating the safety of repeat NeuroNata-R injections and how well…

Top 10 ALS Stories of 2021

ALS News Today brought you daily coverage of the latest scientific breakthroughs and clinical research related to amyotrophic lateral sclerosis (ALS) throughout 2021. We look forward to continuing to report for the ALS community in 2022. Here are the 10 most-read ALS news articles of the last year, with…

Phase 3 Trial of Stem Cell Therapy NeuroNata-R Enrolling in Korea

Note: This story was updated March 31, 2021, to note that the ALSummit trial has been approved by the U.S. Food and Drug Administration but will proceed only in Korea; there are no plans to open additional sites in the U.S. or elsewhere. A Phase 3 clinical trial is…